Table 2.
Changes of symptoms and biomarker in the gonadotropin-releasing hormone agonist, low-dose estrogen-progestin combination, and dienogest treatment groups
| GnRHa (26) | LEP (15) | DNG (11) | ||||
|---|---|---|---|---|---|---|
| Before | After 16 weeks of treatment | Before | After 16 weeks of treatment | Before | After 16 weeks of treatment | |
| Menorrhagiab | 16 (61.5) | 0 | 9 (56.3) | 7 (46.7) | 4 (36.4) | 2 (18.2) |
| Dysmenorrheab | 9 (34.6) | 0 | 9 (56.3) | 6 (40.0) | 2 (18.2) | 0 |
| Chronic pelvic painb | 6 (23.1) | 1 (3.8) | 2 (12.5) | 1 (6.3) | 4 (36.4) | 2 (18.2) |
| CA125 (U/mL)a | 203.1 | 36.5* | 237.5 | 25.2* | 255.9 | 26.4* |
aValues are given as mean, bValues are given as n (%), *P<0.01. GnRHa: Gonadotropin-releasing hormone agonist, LEP: Low-dose estrogen-progestin combination, DNG: Dienogest, CA125: Carcinoma antigen 125